NDA 204684 · Eton
Impavido
Miltefosine · Oral · Antileishmanial
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Mar 19, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
42
15 Phase 3, 2 recruiting
FAERS reports
388
377 serious, 121 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 3, 2026.
IMPAVIDO (miltefosine) capsules are indicated in adults and pediatric patients 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for the treatment of: • Visceral leishmaniasis caused by Leishmania donovani [see Clinical Trials (14.1)]. • Cutaneous leishmaniasis caused by Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis [see Clinical Trials (14.2)]. • Mucosal leishmaniasis caused by Leishmania braziliensis [see Clinical Trials (14.3)]. Limitations of Use: • Leishmania species studied in clinical trials evaluating IMPAVIDO were based on epidemiologic data [see Clinical Trials (14.1, 14.2)]. • There may be geographic variation in clinical response of the same Leishmania species to IMPAVIDO [see Clinical Trials (14.1, 14.2)]. • The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated. IMPAVIDO is an antileishmanial drug indicated in adults and pediatric patients 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for the treatment of: • Visceral leishmaniasis due to Leishmania donovani (1). • Cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis , and Leishmania panamensis (1). • Mucosal leishmaniasis due to Leishmania braziliensis (1). Limitations of use Leishmania species evaluated in clinical trials were based on epidemiologic data. There may be geographic variation in the response of the same Leishmania species to IMPAVIDO (1, 14). The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 19, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- IMPAVIDO · MILTEFOSINE 50MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Miltefosine" as an intervention, any sponsor and status, largest first.
- Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)Pivotal-lookingNot yet recruiting
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
NCT07463040 · 900 participants (planned) · Start Jan 1, 2027 · Primary completion Mar 1, 2029
Drug: Sodium Stibogluconate (SSG); Miltefosine and 3 more · For: Cutaneous Leihmaniasis
Sites: Addis Ababa, Ethiopia; Arba Minch, Ethiopia; Boru, Ethiopia
- Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral LeishmaniasisPivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT00696969 · 634 participants · Start Jun 2008 · Primary completion Jan 2010
Drug: Amphotericin B Deoxycholate; Ambisome + Miltefosine and 2 more · For: Visceral Leishmaniasis
Sites: Muzaffarpur, India; Patna, India
- Combination Therapy in Indian Visceral LeishmaniasisPivotal-lookingCompleted
Banaras Hindu UniversityAcademic, hospital or other
NCT00523965 · 624 participants (planned) · Start Sep 2007 · Primary completion Aug 2009
Drug: amphotericin B deoxycholate; Liposomal Amphotericin B with Miltefosine and 2 more · For: Leishmaniasis, Visceral
Sites: Muzaffarpur, India
- Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in BangladeshPivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT01122771 · 602 participants · Start May 2010 · Primary completion Mar 2014
Drug: Liposomal amphotericin B; liposomal amphotericin B + miltefosine and 2 more · For: Visceral Leishmaniasis
Sites: Bhaluka, Bangladesh; Gafargaon, Bangladesh; Trishal, Bangladesh · 4 sites in all
- Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern AfricaPivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT03129646 · 439 participants · Start Jan 24, 2018 · Primary completion Dec 11, 2020
Drug: Miltefosine; Paromomycin and 1 more · For: Visceral Leishmaniasis
Sites: Ābderafī, Ethiopia; Gonder, Ethiopia; Kapenguria, Kenya · 7 sites in all
- Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.Pivotal-lookingCompleted
Universidad de AntioquiaAcademic, hospital or other
NCT00471705 · 437 participants · Start Jun 2006 · Primary completion Aug 2008
Drug: Miltefosine; Glucantime® · For: Cutaneous Leishmaniasis
Sites: Medellín, Colombia
- Miltefosine and GM-CSF in Cutaneous LeishmaniasisPivotal-lookingCompleted
Hospital Universitário Professor Edgard SantosAcademic, hospital or other
NCT03023111 · 300 participants · Start Jun 30, 2017 · Primary completion Aug 9, 2019
Drug: Sbv; Miltefosine plus placebo and 1 more · For: Cutaneous Leishmaniasis
Sites: Manaus, Brazil; Presidente Tancredo Neves, Brazil
- Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)Pivotal-lookingStatus unknown
Dr. Frank Arguello Cancer ClinicIndustry
NCT02366884 · 250 participants (planned) · Start Jul 26, 2011 · Primary completion Dec 31, 2022
Drug: Anti-Bacterial Agents; Anti-Fungal Agents and 1 more · For: Neoplasms
Sites: San José del Cabo, Mexico; Torreón, Mexico
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use122
- drug ineffective109
- nausea59
- drug ineffective for unapproved indication57
- condition aggravated33
- vomiting33
- product use in unapproved indication26
- disease recurrence24
- decreased appetite22
- visceral leishmaniasis20
- renal failure18
- acute kidney injury17
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 5 |
| 2013 | 4 |
| 2014 | 16 |
| 2015 | 11 |
| 2016 | 8 |
| 2017 | 23 |
| 2018 | 29 |
| 2019 | 31 |
| 2020 | 32 |
| 2021 | 46 |
| 2022 | 27 |
| 2023 | 31 |
| 2024 | 32 |
| 2025 | 58 |
| 2026 | 29 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Impavido (Miltefosine)
2024 spending
$1.5M
Beneficiaries
20
32 claims
Per beneficiary
$74,009
$598.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $941,083 |
| 2021 | $800,566 |
| 2022 | $1,283,054 |
| 2023 | $1,649,352 |
| 2024 | $1,480,172 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis.
Woerly V, Maynard L, Sanquer A, et al. · Parasitol Res 2009 · Clinical Trial, Multicenter Study
- Topical agents and dressings for fungating wounds.
Adderley UJ, Holt IG · Cochrane Database Syst Rev 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- Miltefosine for new world cutaneous leishmaniasis.
Soto J, Arana BA, Toledo J, et al. · Clin Infect Dis 2004 · Clinical Trial, Multicenter Study
- Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Soto J, Rea J, Balderrama M, et al. · Am J Trop Med Hyg 2008 · Randomized Controlled Trial
- Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Vélez I, López L, Sánchez X, et al. · Am J Trop Med Hyg 2010 · Clinical Trial, Phase III, Multicenter Study
- Topical agents and dressings for fungating wounds.
Adderley U, Smith R · Cochrane Database Syst Rev 2007 · Systematic Review
Sponsor: Eton
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.